




# SINTILIMAB

PD-1 INHIBITOR

**LOXO** @Lilly

*The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.*



MHC can be MHC I or MHC II

## TARGET

The interaction of programmed cell death protein 1 (PD-1) transmembrane protein receptor, which is found in lymphocytes and monocytes, with its natural ligands programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2), is one of the major pathways exploited by cancer cells for immune evasion.<sup>1-3</sup> The PD-1/ligand interactions strongly counteract T-cell antigen receptor (TCR) signal transduction and subsequently attenuate cytokine production, T-cell survival, and proliferation.<sup>4</sup>

## MOLECULE

Sintilimab is a recombinant, fully human anti-PD-1 monoclonal antibody that has been shown in preclinical studies to bind to PD-1 and block interactions between PD-1 and PD-L1/PD-L2 to restore antitumor immunity.<sup>5</sup> Sintilimab enhances T-cell function, including antitumor responses, through blockade of PD-1 binding to PD-L1 and PD-L2, which are expressed in antigen presenting cells.<sup>5,6</sup>

## CLINICAL DEVELOPMENT

Sintilimab is being investigated in a clinical trial in patients with advanced solid tumors.

**References:** 1. Agata Y, et al. *Int Immunol*. 1996;8(5):765-772. 2. Ishida Y, et al. *EMBO J*. 1992;11(11):3887-3895. 3. Marin-Acevedo JA, et al. *J Hematol Oncol*. 2018;11(1):39. 4. Chen L, Flies DB. *Nat Rev Immunol*. 2013;13(4):227-242. 5. Wang J, et al. *MAbs*. 2019;11(8):1443-1451. 6. Zhang S, et al. *Antib Ther*. 2018;1:65-73.

**The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.**

## ACTIVE TRIAL CURRENTLY NOT ENROLLING

---

### **[NCT03607539] Lung Cancer**

ORIENT-11: Efficacy and Safety Evaluation of Sintilimab in Patients  
With Advanced or Metastatic Nonsquamous NSCLC



Pipeline information is current through August 4, 2022.

WV-0THR-US-DEL-1049 08/2022 PRINTED IN USA

© Lilly USA, LLC 2022. All rights reserved.

Printed on post-consumer recycled paper. ♻️